Dry oral powders are blended on a production-scale double-cone or paddle mixer operated at 15–25 rpm and 45–60% vessel fill. The veterinary-grade compound probiotic API, typically lyophilised or spray-dried to water activity below 0.20 and standardised to 1×10¹⁰–1×10¹¹ CFU/g by ISO 4833-1:2013, is first extended with a carrier consisting of lactose monohydrate (80–90% w/w), maltodextrin (5–10% w/w) and colloidal silicon dioxide (0.3–0.8% w/w). The blend is passed through a 250 µm stainless-steel sieve before bulk storage and final packaging. Finished-powder moisture is maintained at ≤3.0% w/w and water activity at ≤0.25 according to USP <922>; batch uniformity is verified on samples drawn from top, middle and discharge-port positions, with between-location variability held at ≤0.15 log10 CFU/g. The dominant production-scale failure mode is moisture ingress during filling and heat-sealing: packaging areas should remain below 30% RH, and the dry powder should not be held in unlined fibre drums for more than 4 h when ambient humidity exceeds 60% RH. For preruminant calves and lambs, the powder is dispersed in milk replacer or drench water at a dose equivalent to 1×10⁸–1×10⁹ CFU per animal per day; drinking-water systems are flushed and free chlorine residual is held below 0.3 mg/L to avoid oxidation of vegetative Lactobacillus and Enterococcus cells. Field monitoring of lyophilised powders containing Bacillus subtilis, Bacillus licheniformis, Enterococcus faecium, Lactobacillus acidophilus and Saccharomyces cerevisiae indicates that bulk density and flowability remain stable only when the packaging laminate has a moisture vapour transmission rate below 0.1 g/m²/day at 38°C/90% RH.

Granule growth regimes in high-shear mixer granulation with spore-forming probiotic strains

Wet granulation of the compound API into oral dosage granules is performed in a high-shear granulator with impeller speed 120–180 rpm, chopper speed 1200–1800 rpm, and wet massing time 60–180 s. A binder solution of pregelatinised starch or povidone K30 at 3–5% w/w is cooled to 10–15°C before addition; total water input is 12–18% w/w. The granulation endpoint is controlled by power-consumption profile rather than time alone, with end-of-granulation moisture at 14–18% w/w. Drying is conducted in a fluid-bed dryer with inlet air temperature 38–42°C and product temperature held at 27–31°C until final moisture is ≤3.5% w/w. Granule size is verified with ISO 3310-1 sieves to d50 200–350 µm, with fines below 75 µm limited to ≤15% w/w. Field data show lactobacilli may lose 0.5–1.5 log10 CFU/g when wet-mass temperature exceeds 31°C during massing or early drying; spore-forming Bacillus constituents tolerate the same window with less than 0.2 log10 loss. Granules are packed in single-dose sachets or bulk foil-lined sacks, and the finished granule is dispersed in drinking water at 1×10⁶–1×10⁷ CFU/mL at the trough. For oral topdress applications in piglet and calf starter feeds, the granular form is preferred because granule dust is lower than that of dry powder, and the denser structure resists segregation in transit and in farm storage bins; bulk density is typically 0.45–0.60 g/cm³ with angle of repose below 35°.

At feed-mill scale, the compound probiotic API is first extended in a separate fine carrier such as ground rice hulls, soybean mill feed or calcium carbonate with average particle size 150–300 µm. A preliminary 1:10 dilution is prepared in a small ribbon mixer, then incorporated into a vitamin-mineral premix at total inclusion of 0.5–2.0 kg per metric ton of finished feed. This two-step dilution is required because direct addition of API concentrate into a mixer already containing copper sulphate, zinc oxide and free choline chloride produces local water-activity and oxidative microenvironments that reduce viable count before the batch is homogeneous. Coated trace minerals and low-dust carriers are specified; non-protected choline chloride is loaded only after the probiotic dilution has been dispersed in the main batch. Mixing is performed for 8–15 min at 20–30 rpm, with batch uniformity measured on 10 sampling points to a target coefficient of variation ≤5%. The finished premix moisture is kept below 4.0% w/w and stored below 25°C. Pelleting after premix addition is the principal process conflict: conditioning at 65–80°C for 20–60 s reduces vegetative Lactobacillus and Enterococcus viability by 1–3 log10 CFU/g, whereas Bacillus spore counts may remain within 0.5 log10 of initial. When heat-treated feeds are unavoidable, post-pelleting liquid application onto cooled pellets is used, but the rehydrated suspension must be consumed within 12–24 h because rehydrated probiotic cells are not protected by the dry premix matrix.

What Are the Viability Boundaries for Tablet Compression of Enterococcus faecium Blends?

Tablet compression of veterinary probiotics is not a simple powder compaction step because the vegetative cells and spore coats respond differently to mechanical load. A direct-compression blend for a 500 mg chewable tablet typically contains the lyophilised compound API at 20–30% w/w, microcrystalline cellulose (25–40% w/w), lactose monohydrate (30–45% w/w), crospovidone (2–4% w/w) and magnesium stearate (0.25–0.5% w/w). Blending is limited to 10–15 min in a V-shell blender at 12–18 rpm after addition of magnesium stearate, because extended lubricant blending increases hydrophobic surface coverage and delays disintegration. Compression is performed on an instrumented 10–16-station rotary press at 20–35 rpm and 4.0–8.0 kN compaction force; tablet hardness is monitored at 35–70 N, friability at ≤1.0% by USP <1216>, and disintegration at ≤15 min by USP <701>. At compaction forces above 10 kN, the combination of shear and adiabatic heating in the die wall increases viable loss by more than 1.0 log10 CFU/g for Lactobacillus acidophilus, whereas spore-forming Bacillus subtilis can tolerate compaction forces up to 12 kN with losses below 0.5 log10. Tablet coating, if required, is applied as an aqueous film coat with bed temperature held at 35–38°C and spray rate 8–12 g/min per 24-inch pan; higher bed temperatures are not used for vegetative probiotic tablets. Final blisters should include a desiccant canister or use Aclar/PVC laminate because core moisture is near 2.5–3.5% w/w and moisture ingress accelerates cell death during storage at 30°C/65% RH.

Because capsule shells contribute water and often carry equilibrium moisture of 13–16% w/w for gelatin or 7–9% w/w for HPMC, capsule filling is performed in an environment controlled to 30–35% RH and 20–22°C. The powder blend for capsules is dry-mixed with 0.5–1.0% fumed silica to maintain flow into a dosator or tamping-pin capsule loader; fill weights of 100–400 mg are typical for veterinary companion-animal or calf use, depending on the labelled count of 1×10⁸–1×10⁹ CFU per capsule. The process uses a low-shear V-shell blender at 10–15 rpm for 8–12 min, and the hopper is not left uncovered for more than 15 min when room dew point exceeds 10°C. Weight variation is evaluated on 20 capsules per batch with acceptance criteria of USP <905>. The main viability risk in capsules is not mechanical shear but moisture transfer from the shell wall into the dry fill; this is controlled by storing finished capsules in HDPE bottles with desiccant and maintaining headspace relative humidity below 25%. Delayed-release capsule systems are not ordinarily specified for veterinary probiotic preparations because the dry API is already formulated to survive gastric transit through strain selection rather than through a pH-sensitive shell.

When the API Is Suspended in Oral Solutions, Water Activity and Osmolarity Dictate the Dispensing Interval

Aqueous suspensions prepared from dry probiotic powders leave the dry-stability window immediately after reconstitution. For swine and poultry drinking-water administration, the compound API is dispersed in a buffered vehicle containing 20–30% glycerol, 0.2–0.4% w/w xanthan gum and citrate or acetate buffer to hold pH at 4.8–5.8. The suspension is standardised to 1×10⁸ CFU/mL at manufacture and delivered through a proportioner at 0.5–2.0% dilution into drinking lines. Water quality determines the real-world dose: free chlorine residual must remain below 0.1 mg/L, iron below 0.3 mg/L, and temperature below 25°C at the drinker. In such a system, vegetative Lactobacillus counts decline at approximately 0.5–1.0 log10 CFU/mL per 24 h at 25°C; the prepared suspension is therefore designated a 24 h use period unless refrigerated and re-validated for 72 h. Preservative systems based on potassium sorbate or benzoic acid are avoided because the undissociated acid forms at pH below 5.0 and suppresses the same Gram-positive lactobacilli that the compound API is intended to deliver. The finished oral solution is not subjected to terminal sterilisation; it is filled under ISO 14644-1 Class 8 or better and tested by ISO 4833-1:2013 for total aerobic count and by ISO 21528-2:2017 for absence of Enterobacteriaceae.

Injectable administration is constrained by particulate and pyrogen release thresholds rather than simple sterility

Injectable administration of live compound probiotic cells does not have an established industrial veterinary dosage form. A sterile suspension would need to satisfy USP <71> for sterility, USP <85> for bacterial endotoxins, and USP <788> for subvisible particulate matter; live bacterial cells themselves fall within particulate size ranges and can trigger pyrogenic response pathways even when the preparation is sterile. If an injectable product is considered, the only technically coherent route is an inactivated bacterial lysate or purified subcellular fraction, which would no longer be a live compound probiotic API and would require separate identity, potency and immunotoxicity validation. Published data for this specific veterinary configuration is limited; therefore, tablet, capsule, powder, granule, premix and oral solution applications remain the only dosage forms supported by current industrial data. Intramuscular or subcutaneous injection of live Bacillus spores or Lactobacillus suspensions is not supported by safety data under USP <797> compounding risk levels and must not be compounded without a separate sterile-product development program.